Literature DB >> 19786206

Iron-refractory iron deficiency anemia.

Karin E Finberg1.   

Abstract

Iron-refractory iron deficiency anemia (IRIDA) is an autosomal recessive disorder characterized by iron deficiency anemia unresponsive to oral iron treatment but partially responsive to parenteral iron therapy. IRIDA has recently been shown to be caused by mutations in the gene TMPRSS6, which encodes a transmembrane serine protease (also known as matriptase-2) expressed by the liver. IRIDA patients show inappropriately elevated levels of hepcidin, a circulating hormone produced by the liver that inhibits both iron absorption from the intestine and iron release from macrophage stores. Recent studies suggest that TMPRSS6 normally acts to downregulate hepcidin expression by cleaving hemojuvelin, a membrane-bound protein that promotes hepcidin signaling in hepatocytes. A discussion of the clinical presentation of IRIDA, the molecular genetics of this disorder, and recent studies elucidating the underlying pathophysiology are presented.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19786206     DOI: 10.1053/j.seminhematol.2009.06.006

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  27 in total

1.  Rescuing iron-overloaded macrophages by conservative relocation of the accumulated metal.

Authors:  Yang-Sung Sohn; Anna-Maria Mitterstiller; William Breuer; Guenter Weiss; Z Ioav Cabantchik
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

Review 2.  Hepcidin and HFE protein: Iron metabolism as a target for the anemia of chronic kidney disease.

Authors:  Elena Canavesi; Carlo Alfieri; Serena Pelusi; Luca Valenti
Journal:  World J Nephrol       Date:  2012-12-06

Review 3.  Hepcidin and iron regulation in health and disease.

Authors:  Robert T Means
Journal:  Am J Med Sci       Date:  2013-01       Impact factor: 2.378

Review 4.  Anemia of inflammation.

Authors:  Elizabeta Nemeth; Tomas Ganz
Journal:  Hematol Oncol Clin North Am       Date:  2014-05-28       Impact factor: 3.722

Review 5.  Low hemoglobin deferral in blood donors.

Authors:  Alan E Mast
Journal:  Transfus Med Rev       Date:  2013-11-12

6.  Cuprizone Administration Alters the Iron Metabolism in the Mouse Model of Multiple Sclerosis.

Authors:  E Varga; E Pandur; H Abrahám; A Horváth; P Ács; S Komoly; A Miseta; K Sipos
Journal:  Cell Mol Neurobiol       Date:  2018-02-20       Impact factor: 5.046

7.  Associations of common variants in HFE and TMPRSS6 with iron parameters are independent of serum hepcidin in a general population: a replication study.

Authors:  Tessel E Galesloot; Anneke J Geurts-Moespot; Martin den Heijer; Fred C G J Sweep; Robert E Fleming; Lambertus A L M Kiemeney; Sita H Vermeulen; Dorine W Swinkels
Journal:  J Med Genet       Date:  2013-06-21       Impact factor: 6.318

8.  Hepcidin and ferroportin expression in breast cancer tissue and serum and their relationship with anemia.

Authors:  X Pan; Y Lu; X Cheng; J Wang
Journal:  Curr Oncol       Date:  2016-02-18       Impact factor: 3.677

9.  Iron refractory iron deficiency anemia: presentation with hyperferritinemia and response to oral iron therapy.

Authors:  Dong-Anh Khuong-Quang; Jeremy Schwartzentruber; Mark Westerman; Pierre Lepage; Karin E Finberg; Jacek Majewski; Nada Jabado
Journal:  Pediatrics       Date:  2013-01-14       Impact factor: 7.124

10.  An unusual case of iron deficiency anemia is associated with extremely low level of transferrin receptor.

Authors:  Shuangying Hao; Huihui Li; Xiaoyan Sun; Juan Li; Kuanyu Li
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.